HIV Type 1 V3 domain serotyping and genotyping in Gauteng, Mpumalanga, KwaZulu-Natal and Western Cape provinces of South Africa

dc.contributor.authorEngelbrecht, Susan
dc.contributor.authorSmith, Tracey-Lee
dc.contributor.authorKasper, P.
dc.contributor.authorFaatz, E.
dc.contributor.authorZeier, Michelle D.
dc.contributor.authorMoodley, D.
dc.contributor.authorJanse van Rensburg, Estrelita
dc.contributor.upauthorClay, Cornelius G.
dc.date.accessioned2007-08-15T11:53:31Z
dc.date.available2007-08-15T11:53:31Z
dc.date.issued1999
dc.descriptionThe publisher does not allow open access to the full text of this short communication. If you however need access to the full text, please contact the Collection Administrator, or access the item via the e-journal collection.en
dc.description.abstractMore than 20.8 million people are living with HIV/AIDS in sub-Saharan Africa, with southern Africa the worst affected area and accounting for one of the fastest growing AIDS epidemics worldwide. Samples from 81 patients, including 25 from KwaZulu-Natal, 26 from Gauteng, 5 from Mpumalanga, and 25 from Western Cape Province, were serotyped using a competitive V3 peptide enzyme immunoassay (cPEIA). Viral RNA was also isolated from serum and the V3 region amplified by reverse transcriptase polymerase chain reaction (RTPCR) to obtain a 240-bp product for direct sequencing of 29 samples. CLUSTAL W was used to make multiple sequence alignments. Distance calculation, tree construction methods, and bootstrap analysis were done using TREECON. Subtype C-like V3 loop sequences predominate in all provinces tested in South Africa. Discordant sero- and genotype results were observed in one patient only. The correlation between sero- and genotyping was 96% (24 of 25) in KwaZulu-Natal and 100% in Gauteng and Mpumalanga. In Western Cape Province 18% of patients were identified as sero/genotype B and 82% as sero/genotype C. Our data show that results of the second-generation V3 cPEIA correlated well with V3 sequencing and would be a rapid and affordable screening test to monitor the explosive southern African HIV-1 epidemic.en
dc.description.sponsorshipThis work was supported by grants of the Poliomyelitis Research Foundation (PRF), the Medical Research Council (MRC), and the Harry Crossley Foundation. We thank Ms. Sharon McLaren, SAIMR Themba Hospital, for the Mpumalanga samples.en
dc.format.extent124589 bytes
dc.format.mimetypeapplication/pdf
dc.identifier.citationEngelbrecht, S, Smith, T-L, Kasper, P, Faatz, E, Zeier, M, Moodley, D, Clay, CG & Janse van Rensburg, E 1999, 'HIV Type 1 V3 domain serotyping and genotyping in Gauteng, Mpumalanga, KwaZulu-Natal and Western Cape Provinces of South Africa', AIDS Research and Human Retroviruses, vol. 15, no. 4, pp. 325-328. [http://www.liebertpub.com/publication.aspx?pub_id=2]en
dc.identifier.issn0889-2229
dc.identifier.urihttp://hdl.handle.net/2263/3297
dc.language.isoenen
dc.publisherMary Ann Lieberten
dc.rightsMary Ann Liebert.en
dc.subject.lcshHIV infections -- South Africa
dc.subject.lcshAIDS (Disease) -- Research -- South Africa
dc.titleHIV Type 1 V3 domain serotyping and genotyping in Gauteng, Mpumalanga, KwaZulu-Natal and Western Cape provinces of South Africaen
dc.typeTexten

Files

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
2.39 KB
Format:
Item-specific license agreed upon to submission
Description: